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ABSTRACT
The aim of the present study was to examine whether there is a relationship between autonomic function and post-challenge
hyperglycemia in patients with type 2 diabetes. Subjects included 122 Japanese patients newly diagnosed with type 2 diabetes.
Autonomic nerve function was assessed using coefﬁcients of variation of the R-R intervals on electrocardiograms (CVRR).
Unlike anthropometry, insulin secretion and insulin resistance, age (r = )0.209, P < 0.021) and post-challenge plasma glucose
at 120 min (PG120; r = )0.219, P < 0.015) were the only variables signiﬁcantly correlated with CVRR. Age was not signiﬁcantly
correlated with PG120. In multiple regression analyses, CVRR Z-score, but not age, was signiﬁcantly correlated with PG120. The
present results suggest that autonomic function affects post-challenge blood glucose levels independently of age. (J Diabetes Invest,
doi: 10.1111/j.2040-1124.2010.00098.x, 2011)
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INTRODUCTION
Diabetic autonomic neuropathy is a major complication in
patients with diabetes; it decreases quality of life and increases
mortality. Long-term hyperglycemia is a primary cause of dia-
betic neuropathy1. Conversely, autonomic function might affect
glycemic control through gastrointestinal peristalsis. In addition,
results from animal experiments have suggested that the auto-
nomic nervous system contributes to glucose homeostasis
by mediating interorgan networks2–4. Matsuhisa et al. have
reported that the vagus nerve, which in part controls the liver,
plays an important role in regulating postprandial glucose lev-
els5,6. In addition, the intestinal–brain–liver neuronal axis has
been reported to be involved in liver gluconeogenesis4. However,
evidence showing that these pathways and autonomic function
play a role in glycemic control is lacking in humans. The aim of
the present study was to examine whether there is a relationship
between autonomic function, evaluated by coefﬁcient of varia-
tion of the R-R interval on electrocardiograms (ECG; CVRR),
and post-challenge hyperglycemia in patients with newly diag-
nosed type 2 diabetes.
MATERIAL AND METHODS
Subjects
A total of 122 Japanese patients newly diagnosed with type 2
diabetes mellitus between January 2008 and December 2009, in
the Division of Endocrinology and Metabolism at Kanazawa
University Hospital, were recruited for the present study. None
of the patients were treated with an oral hypoglycemic agent or
insulin. Table 1 shows the demographic, clinical and physical
characteristics of the subjects.
Written informed consent was obtained from all patients
before initiation of the study. The study was approved by the
ethics committee established at the Kanazawa University Hospi-
tal (Approval No. 729) and was carried out in accordance with
the Declaration of Helsinki.
Laboratory Data
HbA1c was described in the Japan Diabetes Society (JDS) value.
Oral glucose tolerance tests using 75 g of glucose (75-g OGTT)
were carried out for all patients. The plasma glucose concentra-
tion was measured using an automated glucose analyzer (model
GA08; ATWiLL M.I., Kanazawa, Japan). The plasma insulin
concentration was measured by immunoassay (AIA-1800ST;
Tosoh, Tokyo, Japan).
Insulin resistance in the liver was evaluated using the liver
insulin resistance index (L-IR) as reported by Muhammad
et al.7. Insulin resistance in muscle was evaluated using the muscle
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insulin resistance index (M-IR) as reported by Matsuda et al.8.
To evaluate initial insulin secretion, the insulinogenic index was
calculated by dividing the change in immunoreactive insulin
(IRI) over 30 min by the change in plasma glucose (PG) over
30 min: DIRI (30¢ – 0¢) lU/mL/DPG (30¢ – 0¢) mg/dL.
Evaluation of Autonomic Nerve Function
The CVRR was used to evaluate diabetic autonomic neuro-
pathy9. After the patient had rested in the supine position for at
least 10 min, a standard 12-lead ECG was recorded (Cardio Star
FCP-7541; Nihon Kohden, Tokyo, Japan). The R-R intervals
were measured for 3 min, and the CVRR was obtained by
dividing the standard deviations (SD) by the means (M):
CV (%) = (SD/M) · 100. Because CVRR is inﬂuenced by age,
we also used CVRR Z-score calculated by (CVRR-mean
CVRR)/SD-CVRR in each age category to the age-speciﬁc
normal value of CVRR (Table S2).
Statistical Analysis
For statistical analyses, SPSS II for Windows (SPSS, Chicago, IL,
USA) was used. Single regression analysis and multiple regres-
sion analysis were used to examine associations between CVRR
and clinical parameters. All data are presented as means ± SD.
RESULTS
Clinical characteristics of the 122 newly diagnosed type 2 dia-
betic patients are shown in Table 1. The prevalence of retino-
pathy and nephropathy was 21% and 25% of the subjects,
respectively. When somatic polyneuropathy is deﬁned as below
mean-2SD in nerve conduction velocity in more than two of six
sites in the healthy subjects, its prevalence was 18%.
The results for single linear regression analyses between
CVRR and each clinical parameter are shown in Table 2. CVRR
was signiﬁcantly correlated with age (r = )0.209, P < 0.021)
and PG120 (r = )0.219, P < 0.015; Table 2), but was not corre-
lated with body mass index, HbA1c, insulinogenic index, PG0-60
and IRI0-120, L-IR, and M-IR (P > 0.05; Table 2). Although
CVRR diminishes with age, CVRR, but not age, signiﬁcantly
correlated to PG120 (Table S1). In a multiple regression analysis
for PG 120 as a dependent variable, CVRR was still signiﬁcantly
correlated with PG120 (P = 0.004), even after adjustment
for age (Table 3, upper panel). When we used CVRR Z-scores
in the analysis, CVRR Z score, but not age, was signiﬁcantly
correlated with PG120 in a multiple regression model (Table 3,
lower panel).
Table 1 | Clinical characteristics of the 74 newly diagnosed type 2
diabetic patients
Clinical parameters Value
Age (years) 60.1 ± 11.1
Sex (male/female) 82/40
Body mass index (kg/m2) 25.1 ± 4.7
Fasting plasma glucose (mg/dL) 139.9 ± 31.8
HbA1c (%) (JDS) 7.9 ± 2.0









Stage 1 90/120 75
Stage 2 19/120 16
Stage 3a 7/120 6
Stage 3b 3/120 3
Stage 4 1/120 1
Somatic polyneuropathy‡ 17/95 18
Data are means ± SD. JDS, Japan Diabetes Society. †Retinopathy
stages were diagnosed according to Fukuda’s classiﬁcation (Fukuda
M. Classiﬁcation and treatment of diabetic retinopathy. Diabetes Research
and Clinical Practice. 1994; 24 Suppl: s171–s176) as follows: Stage 0,
patients without retinopathy; Stage A1, mild to moderate simple
retinopathy; Stage A2, severe simple retinopathy; Stage A3, mild to
moderate interrupted proliferative retinopathy; Stage A4, 5, severe
interrupted proliferative retinopathy; Stage B1, pre-proliferative diabetic
retinopathy; Stage B2, early proliferative diabetic retinopathy; Stage B3,
advanced proliferative diabetic retinopathy; Stage B4, end-stage
proliferative diabetic retinopathy. ‡Somatic polyneuropathy was deﬁned
as below mean-2SD in nerve conduction velocity in two or more of
six sites in the healthy subject.
Table 2 | Single linear regression analyses between coefﬁcients of





HbA1c (JDS) 0.057 0.536











*P < 0.05. PG0, plasma glucose concentration before load; PG30, plasma
glucose concentrations at 30 min after load; PG60, plasma glucose con-
centrations at 60 min after load; PG120, plasma glucose concentrations
at 120 min after load; IRI0, immunoreactive insulin before load; IRI30,
immunoreactive insulin at 30 min after load; IRI60, immunoreactive
insulin at 60 min after load; IRI120, immunoreactive insulin at 120 min
after load; L-IR, liver insulin resistance index; M-IR, muscle insulin
resistance index.
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DISCUSSION
The preset results suggest that autonomic nerve dysfunction,
speciﬁcally parasympathetic nerve dysfunction, increases
post-challenge glucose levels without affecting insulin secretion
or insulin sensitivity. One possible mechanism underlying
autonomic dysfunction-associated post-challenge hyperglycemia
is gastrointestinal peristalsis that affects absorption of
nutrients10.
The failure of liver gluconeogenesis, regulated by the vagus
nerve, has been shown to contribute to diabetic autonomic neu-
ropathy-related hyperglycemia. Wang et al.4 reported that lipids
in the upper intestine activate the intestine–brain–liver neural
axis to inhibit glucose production. This mechanism, which
inhibits liver gluconeogenesis after food consumption, is medi-
ated through the vagus nerve, which innervates the small intes-
tine from the cerebrum. We suspect that dysfunction of this
mechanism caused by diabetic autonomic neuropathy might
contribute to hyperglycemia.
The neuronal pathway might mediate the action of incretin
hormones secreted by the gut, such as glucagon-like peptide-1
(GLP-1) and glucose-dependent gastric inhibitory peptide (GIP).
Incretin hormones enhance glucose-mediated insulin secretion
and suppress exaggerated glucagon secretion11–14, thereby regu-
lating postprandial plasma glucose levels.
Diabetic autonomic neuropathy might also cause the dysfunc-
tion of cardiovascular, gastrointestinal, genitourinary, sudomotor
or ocular organs1. Postprandial and post-challenge hyperglycemia
is an independent risk factor for macrovascular disease15–17 as
well as many other complications, such as diabetic retinopathy18,
increased carotid intima-media thickness19, increased oxidative
stress20, decreased myocardial blood volume and myocardial
blood ﬂow21, increased risk for cancer22, and impaired cogni-
tive function23. Further studies are needed to clarify whether
diabetic autonomic neuropathy increases the risks for these
complications.
In conclusion, the present results suggest that autonomic
function affects post-challenge blood glucose levels indepen-
dently of age in patients with type 2 diabetes.
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